Terns Pharmaceuticals to Present Clinical Data on Multiple NASH Programs at the EASL International Liver Congress 2022
June 08 2022 - 4:05PM
Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq:
TERN), a clinical-stage biopharmaceutical company developing a
portfolio of small-molecule single-agent and combination therapy
candidates to address serious diseases such as non-alcoholic
steatohepatitis (NASH), obesity and cancer, today announced that
five abstracts detailing clinical data for multiple non-alcoholic
steatohepatitis (NASH) programs within the Company's portfolio were
accepted for presentation at The International Liver Congress™ 2022
taking place June 22-26 in London, United Kingdom.
The abstracts were published in the July supplement of the
Journal of Hepatology.
Details of the Terns presentations at The International Liver
Congress 2022 are as follows:
Oral PresentationTitle:
Multiple doses of thyroid hormone receptor-beta agonist TERN-501
were well-tolerated and resulted in significant dose-dependent
changes in serum lipids and sex hormone binding globulin in a
first-in-human clinical studyPublication Number:
OS123Presenter: Cara NelsonDate and
Time: Saturday, June 25 6:15 p.m. BT
Poster PresentationsTitle:
Favorable lipid and pruritus profile of liver-distributed farnesoid
X receptor agonist TERN-101 at clinically efficacious doses in
nonalcoholic steatohepatitis phase 2a LIFT studyPublication
Number: SAT107Presenter: Kris Kowdley
Title: Liver-distributed farnesoid X receptor
agonist TERN-101 demonstrates potent target engagement with a
favorable exposure-response profile in nonalcoholic steatohepatitis
patientsPublication Number:
SAT108Presenter: Cara Nelson
Title: TERN-101, a farnesoid X receptor
agonist, demonstrated similar safety and efficacy in nonalcoholic
steatohepatitis patients with coronavirus disease of 2019
(COVID-19) exposure compared to those with no COVID-19 exposure in
phase 2a LIFT studyPublication Number:
SAT106Presenter: Kris Kowdley
Title: Favorable safety profile of TERN-201, a
highly selective inhibitor of vascular adhesion protein-1, in the
nonalcoholic steatohepatitis phase 1b AVIATION
studyPublication Number:
SAT142Presenter: Mazen Noureddin
About Terns PharmaceuticalsTerns
Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company
developing a portfolio of small-molecule single-agent and
combination therapy candidates to address serious diseases such as
NASH, obesity and cancer. Terns’ pipeline includes four clinical
stage development programs including a THR-β agonist, an allosteric
BCR-ABL inhibitor, an FXR agonist, a VAP-1 inhibitor, and a
preclinical small-molecule GLP-1 receptor agonist program. For more
information, please visit: www.ternspharma.com.
Contacts for Terns
InvestorsJustin
Nginvestors@ternspharma.com
MediaJenna UrbanBerry & Company Public
Relationsmedia@ternspharma.com
Terns Pharmaceuticals (NASDAQ:TERN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Terns Pharmaceuticals (NASDAQ:TERN)
Historical Stock Chart
From Apr 2023 to Apr 2024